LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Ligand Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

184.08 -1.31

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

178.73

Max

187.57

Belangrijke statistieken

By Trading Economics

Inkomsten

112M

117M

Verkoop

115M

K/W

Sectorgemiddelde

81.987

121.746

Winstmarge

101.569

Werknemers

68

EBITDA

87M

149M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+26.89% upside

Dividenden

By Dow Jones

Volgende Winsten

26 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-440M

3.7B

Vorige openingsprijs

185.39

Vorige sluitingsprijs

184.08

Nieuwssentiment

By Acuity

20%

80%

29 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 feb 2026, 23:47 UTC

Populaire aandelen

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 feb 2026, 22:59 UTC

Winsten
Acquisities, Fusies, Overnames

Grab Holdings to Buy U.S.-Based Stash Financial

11 feb 2026, 23:54 UTC

Winsten

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 feb 2026, 23:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

11 feb 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 feb 2026, 23:49 UTC

Winsten

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 feb 2026, 23:45 UTC

Winsten

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 feb 2026, 23:42 UTC

Winsten

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 feb 2026, 23:41 UTC

Winsten

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 feb 2026, 23:40 UTC

Winsten

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 feb 2026, 23:35 UTC

Marktinformatie

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 feb 2026, 23:18 UTC

Marktinformatie

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 feb 2026, 23:14 UTC

Marktinformatie

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 feb 2026, 22:59 UTC

Winsten

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 feb 2026, 22:59 UTC

Winsten

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 feb 2026, 22:59 UTC

Winsten

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 feb 2026, 22:58 UTC

Winsten

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 feb 2026, 22:57 UTC

Winsten

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 feb 2026, 22:54 UTC

Winsten

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 feb 2026, 22:53 UTC

Winsten

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 feb 2026, 22:47 UTC

Winsten

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb 2026, 22:47 UTC

Winsten

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb 2026, 22:23 UTC

Winsten

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 feb 2026, 22:22 UTC

Winsten

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 feb 2026, 22:22 UTC

Winsten

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 feb 2026, 22:19 UTC

Winsten

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 feb 2026, 22:18 UTC

Winsten

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 feb 2026, 22:18 UTC

Winsten

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 feb 2026, 22:18 UTC

Winsten

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 feb 2026, 22:16 UTC

Winsten

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Peer Vergelijking

Prijswijziging

Ligand Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

26.89% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 237.2 USD  26.89%

Hoogste 270 USD

Laagste 220 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ligand Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technische score

By Trading Central

102.5 / 109.24Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

29 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat